Bone marrow-derived mesenchymal stem cells

Cell therapy

GGuangzhou General Hospital of Guangzhou Military Command

Bone marrow-derived mesenchymal stem cells is one of 112 biologic programs targeting Aplastic Anemia. It is currently in development.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aplastic AnemiaActive, not recruiting

Ischemic StrokeActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Aplastic AnemiaPhase 1/Phase 2

Active, not recruiting

Ischemic StrokePhase 1/Phase 2

Active, not recruiting

Spinal Cord InjuryPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

2 2

Repatha

Amgen

Preclinical

2 3

Levaquin

WWim Janssens

Preclinical

3 4

Tylenol

KKenvue Brands

Preclinical

1 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Actilyse

Boehringer Ingelheim

Preclinical

1 10

Magnesium

SSpherium Biomed

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Mesenchymal Stromal Cells

NCT05095532

Clinical

Trials by Indication[1]

Mesenchymal Stem Cells2 trials

Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage

Completed·RRoyan Institute·Phase 1·NCT00850187·6 enrolled

Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 1/2·NCT01446614·20 enrolled

Aplastic Anemia1 trial

Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 1/2·NCT01305694·50 enrolled

Liver1 trial

Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs

Unknown status·YYamaguchi University Hospital·Phase 1·NCT02327832·10 enrolled

Mesenchymal Stromal Cells1 trial

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

Recruiting·MMedical University of South Carolina·Phase 1·NCT05095532·42 enrolled

Spinal Cord Injury1 trial

Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 1/2·NCT01446640·20 enrolled

1 more indication

Ischemic stroke1 trial

Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke

Withdrawn·UUniversity of California, Irvine·Phase 1/2·NCT01849887

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Bone marrow-derived mesenchymal stem cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bone marrow-derived mesenchymal stem cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bone marrow-derived mesenchymal stem cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou General Hospital of Guangzhou Military Command company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Company: GGuangzhou General Hospital of Guangzhou Military Command

Bone marrow-derived mesenchymal stem cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Mesenchymal Stem Cells2 trials

Aplastic Anemia1 trial

Liver1 trial

Mesenchymal Stromal Cells1 trial

Spinal Cord Injury1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News